The Rit2 protein clears toxic forms of the alpha-synuclein protein from nerve cells, where it manifests as a hallmark symptom of Parkinson’s disease, a study reveals. Targeting Rit2 could represent an effective strategy to combat nerve cell loss in familial and sporadic forms of the disease, its researchers noted.
News
Many people with Parkinson’s disease who take antipsychotic medications begin them shortly after being hospitalized, a new study shows. The finding implies that poorly managed psychiatric problems likely contribute to hospitalizations. The data emphasize the importance of appropriately supporting and monitoring people with Parkinson’s so psychiatric issues can be…
The U.S. Food and Drug Administration (FDA) has agreed that a 42-year-old man with prodromal, or early stage, multiple system atrophy (MSA) , a form of atypical parkinsonism, be treated with ENT-01, Enterin’s investigational therapy for reducing the accumulation of toxic alpha-synuclein in gut nerve cells. Treatment will…
Enrollment is now open across all 38 clinical sites in the Phase 2b trial testing pirepemat  (previously known as IRL752), IRLAB Therapeutics’ investigational therapy intended to treat impaired balance and prevent falls in patients with Parkinson’s disease. The Phase 2b trial (NCT05258071) is recruiting Parkinson’s…
A highly sensitive blood test accurately identified people with synucleinopathies, disorders caused by the abnormal aggregation of the protein alpha-synuclein, such as Parkinson’s disease. The test, called immunoprecipitation-based real-time quaking-induced conversion (IP/RT-QuIC), detected early-formed alpha-synuclein fibrils — or seeds — that eventually grew into disease-causing aggregates. Microscopic analysis detected…
Alterity Therapeutics’ new Phase 2 clinical trial testing ATH434 in patients with multiple system atrophy (MSA), a form of atypical parkinsonism, has enrolled its first patient, the company announced. The open-label, biomarker ATH434-202 study (NCT05864365) is enrolling 15 adults, ages 30-75 years, with advanced MSA and…
Patterns of brain damage in Parkinson’s disease differ based on whether or not individuals have REM sleep behavior disorder (RBD), a new study suggests. Study findings indicate that patterns of brain damage are similar among Parkinson’s patients who develop RBD before or after Parkinson’s motor symptoms. Based on…
In people with Parkinson’s disease, sleep disturbances and excessive daytime sleepiness (EDS) were associated with the impairment of the autonomic nervous system that controls involuntary bodily functions, a study shows. Depression and rapid eye movement sleep behavior disorder (RBD), or dream-enacting behavior, also contributed to problems sleeping at night…
The first patient has been dosed in a Phase 2 trial testing BIA 28-6156, Bial’s investigational therapy for Parkinson’s disease patients with mutations in the glucocerebrosidase 1 (GBA1) gene. The ACTIVATE (NCT05819359) study is currently screening Parkinson’s patients, ages 35 to 80 years, across multiple sites in…
NurrOn Pharmaceuticals has partnered with South Korean HanAll Biopharma and Daewoong Pharmaceutical to continue developing its candidate therapy for Parkinson’s disease and other neurodegenerative disorders. A Phase 1 clinical trial of its lead oral investigational therapy ATH-399A is expected to start this year. Before testing it…
Recent Posts
- Guest Voice: DBS surgery transformed my life with early-onset Parkinson’s
- Smartphone app helps Parkinson’s patients map daily symptoms
- Spinal stimulation found safe, shows mixed benefits in small study
- SCAN brain network may offer new treatment target in Parkinson’s
- Parkinson’s clinical trial recruiting patients at USC, other locations